Congressionally Directed Medical Research Programs (CDMRP) -- Peer Reviewed Cancer Research Program (PRCRP) -- Translational Team Science Award

Funding Agency:
Department of Defense

The FY19 PRCRP Translational Team Science Award (TTSA) supports hypothesis-driven translational studies. These studies should be associated with a clinical trial. The proposed project should focus on research for the next-phase clinical trial or future clinical application. The TTSA is intended to support advanced translational studies that are based on results from clinical investigations. While funding for clinical trials is allowed, the TTSA is intended to support multi-investigator, multidisciplinary teams to perform clinical research studies and not only to fund a clinical trial. Research projects funded by the TTSA should address critical knowledge gaps in clinical outcomes, validate key research results, expand upon potentially game-changing results, or investigate novel clinical findings.

New for FY19: The FY19 PRCRP TTSA Areas of Emphasis (strongly encouraged but not required):

• Interventions to improve quality of life for cancer patients and/or survivors

• Cancer prevention or early detection

• Understanding metastatic disease to improve outcomes

Applications proposing a study not within the scope of the FY19 PRCRP TTSA Areas of Emphasis must demonstrate that the research proposed once translated to the clinic will have lasting impact in the research area studied.

• Pre-Application Deadline: May 22, 2019
• Invitation to Submit an Application: June 2019
• Application Submission Deadline: September 11, 2019

Agency Website

Areas of Interest

To be considered for funding, applications for the FY19 PRCRP Translational Team Science Award must address at least one of the FY19 PRCRP Topic Areas as directed by Congress. Research applications in the areas of breast, prostate, lung (excluding mesothelioma), kidney, melanoma, or ovarian cancer will not be accepted. The FY19 PRCRP Topic Areas are listed below. • Bladder cancer • Blood cancers • Brain cancer • Cancer in children, adolescents, and young adults1 • Colorectal cancer • Immunotherapy2 • Listeria vaccine for cancer • Liver cancer • Lymphoma • Mesothelioma • Neuroblastoma • Pancreatic cancer • Pediatric brain tumors • Rare cancers3 • Stomach cancer

New for FY19: Studies involving melanoma (including rare subtypes of melanoma) should apply to the new FY19 Melanoma Research Program. Studies involving other skin cancers will be accepted by the PRCRP under an appropriate FY19 PRCRP Topic Area (i.e., immunotherapy).

In addition to addressing at least one of the required FY19 PRCRP Topic Areas, applications for the FY19 PRCRP TTSA must also address at least one of the FY19 PRCRP Military Health Focus Areas. Relevance to military in medical research focuses on critical issues or gaps in biomedical knowledge that may affect the health and well-being of the military.  

It is central to the vision and mission of the PRCRP that applications address how the proposed research is related to military health, mission readiness, and the cancer health needs of both deployed and non-deployed military personnel, their dependents, Veterans, and other military beneficiaries (i.e. family members of retirees). The FY19 PRCRP requires all applications address at least one of Military Health Focus Areas listed below:

• Environmental/exposure risk factors associated with cancer

• Gaps in cancer prevention, early detection/diagnosis, prognosis, treatment, and/or survivorship that may impact mission readiness and the health and well-being of military members, Veterans, their beneficiaries, and the general public

Eligibility Requirements

The investigator named as the Initiating PI on the application must be at or above the level of Assistant Professor or equivalent. The investigator(s) named as the Partnering PI(s) on the application must be at or above the level of Assistant Professor or equivalent. Postdoctoral fellows are not eligible to be Initiating or Partnering PIs. It is encouraged that at least one of the PIs be a military or VA investigator.  



Amount Description

The anticipated direct costs budgeted for the entire period of performance for an FY19 PRCRP TTSA award will not exceed $1,500,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information. 

Funding Type



Junior Faculty


Engineering and Physical Sciences
Medical - Basic Science
Medical - Clinical Science
Medical - Translational

External Deadline

May 22, 2019